<p>Handelsbanken Fonder AB 在第二季度增持了 Gilead Sciences, Inc.（NASDAQ:GILD - 免费报告）6.3% 的股份，根据其最近向证券交易委员会提交的 13F 表格。该公司在本季度购买了额外的 69,440 股后，持有生物制药公司 1,164,320 股股票。截至其最近的 SEC 文件，Handelsbanken Fonder AB 持有 Gilead Sciences 约 0.09% 的股份，价值 129,088,000 美元。</p>
<ul>
<li>目前具有高增长潜力的 3 只现金丰富股票</li>
</ul>
<p>其他几家机构投资者最近也对 GILD 的持仓进行了调整。One Wealth Advisors LLC 在第二季度将其在 Gilead Sciences 的股份增加了 34.8%。One Wealth Advisors LLC 目前持有 9,163 股生物制药公司的股票，价值 1,016,000 美元，此前在上个季度购买了额外的 2,364 股。Ariel Investments LLC 在第一季度将其在 Gilead Sciences 的股份增加了 7.7%。Ariel Investments LLC 目前持有 430,424 股生物制药公司的股票，价值 48,229,000 美元，此前在上个季度收购了额外的 30,630 股。Simplify Asset Management Inc. 在第二季度将其在 Gilead Sciences 的股份增加了 148.6%。Simplify Asset Management Inc. 目前持有 52,890 股生物制药公司的股票，价值 5,864,000 美元，此前在上个季度收购了额外的 31,618 股。Sivik Global Healthcare LLC 在第二季度将其在 Gilead Sciences 的持仓增加了 25.0%。Sivik Global Healthcare LLC 目前持有 50,000 股生物制药公司的股票，价值 5,544,000 美元，此前在上个季度收购了额外的 10,000 股。最后，Wealth Management Associates Inc. 在第二季度获得了 Gilead Sciences 的新头寸，价值约 255,000 美元。机构投资者和对冲基金持有该公司 83.67% 的股份。</p>
<p>获取 <strong>Gilead Sciences</strong> 警报：</p>
<h2>分析师设定新目标价</h2>
<p>GILD 最近成为多份研究报告的主题。大和资本市场在 11 月 13 日的报告中将 Gilead Sciences 的目标价从 128.00 美元上调至 129.00 美元，并给予该公司 “跑赢大盘” 的评级。花旗集团在 10 月 8 日的研究报告中将 Gilead Sciences 的目标价从 125.00 美元上调至 135.00 美元，并给予该公司 “买入” 评级。富国银行在 10 月 31 日的报告中将 Gilead Sciences 的目标价从 140.00 美元上调至 145.00 美元，并给予该股票 “增持” 评级。加拿大丰业银行在 11 月 13 日的报告中开始覆盖 Gilead Sciences 的股票。他们给予该公司 “行业跑赢” 的评级和 140.00 美元的目标价。最后，加拿大皇家银行在 10 月 31 日的研究报告中将 Gilead Sciences 的目标价从 100.00 美元上调至 105.00 美元，并给予该公司 “行业表现” 的评级。两位分析师对该股票给予强烈买入评级，二十一位给予买入评级，三位给予持有评级。根据 MarketBeat.com 的数据，该公司目前的共识评级为 “适度买入”，共识目标价为 130.45 美元。</p>
<ul>
<li>生物技术行业可能在年末转变为市场领头羊</li>
</ul>
<p><strong>查看我们关于 GILD 的最新研究报告</strong></p>
<h2>Gilead Sciences 价格表现</h2>
<p>NASDAQ:GILD 的股票在周五开盘价为 124.99 美元。该公司的市值为 1550.7 亿美元，市盈率为 24.90，市盈增长比率为 0.81，贝塔值为 0.32。该公司的 50 日移动平均线为 118.23 美元，200 日移动平均线为 113.37 美元。该公司的债务与股本比率为 1.13，速动比率为 1.15，流动比率为 1.32。Gilead Sciences, Inc. 的 52 周低点为 88.07 美元，52 周高点为 128.70 美元。</p>
<ul>
<li>3 家因美国销售和政策变化而受益的生物技术巨头</li>
</ul>
<p>Gilead Sciences（NASDAQ:GILD - 获取免费报告）最近在 10 月 30 日发布了季度财报。该生物制药公司报告本季度每股收益（EPS）为 2.47 美元，超出分析师共识预期的 2.16 美元，超出幅度为 0.31 美元。该公司本季度的收入为 77.7 亿美元，而共识预期为 74.2 亿美元。Gilead Sciences 的净利润率为 21.86%，股本回报率为 50.99%。该公司的季度收入较去年同期增长了 3.0%。去年同期，该公司每股收益为 2.02 美元。Gilead Sciences 已将其 2025 财年的指导目标设定为 8.050-8.250 每股收益。根据分析师的平均预测，Gilead Sciences, Inc. 预计本年度每股收益为 7.95 美元。</p>
<h2>Gilead Sciences 宣布分红</h2>
<p>该公司最近还披露了季度分红，将于 12 月 30 日（星期二）支付。12 月 15 日（星期一）登记的投资者将获得 0.79 美元的分红。除息日为 12 月 15 日（星期一）。这代表着每年 3.16 美元的分红，收益率为 2.5%。Gilead Sciences 的分红支付比率目前为 48.99%。</p>
<h2>Gilead Sciences 的内部交易</h2>
<p>在其他新闻中，首席财务官安德鲁·D·迪金森于 11 月 17 日星期一出售了 2,500 股该股票。股票的平均售价为 125.23 美元，总交易额为 313,075.00 美元。交易完成后，首席财务官在公司持有 154,555 股，价值约为 19,354,922.65 美元。这代表其持股减少了 1.59%。该交易已在与证券交易委员会的法律文件中披露，您可以通过此超链接访问。此外，首席执行官丹尼尔·帕特里克·奥戴于 10 月 28 日星期二出售了 10,000 股吉利德科学的股票。股票的平均售价为 119.39 美元，总价值为 1,193,900.00 美元。交易完成后，首席执行官直接持有 581,203 股公司股票，价值约为 69,389,826.17 美元。这笔交易代表其持股减少了 1.69%。有关此次出售的更多细节可在官方 SEC 披露中找到。在过去三个月中，内部人士共出售了 125,146 股公司股票，价值为 15,148,441 美元。目前，0.27% 的股票由公司内部人士持有。</p>
<h2>关于吉利德科学</h2>
<p>（免费报告）</p>
<p>吉利德科学公司是一家生物制药公司，在美国、欧洲及国际上发现、开发和商业化满足医疗需求的药物。该公司提供 Biktarvy、Genvoya、Descovy、Odefsey、Truvada、Complera/Eviplera、Stribild、Sunlencs 和 Atripla 等产品用于治疗 HIV/AIDS；Veklury，一种用于静脉注射的药物，用于治疗 COVID-19；以及 Epclusa、Harvoni、Vemlidy 和 Viread 用于治疗病毒性肝炎。</p>
<h2>精选文章</h2>
<ul>
<li>我们更看好的五只股票超过吉利德科学</li>
<li>零售股票投资解析</li>
<li>Datavault AI 刚刚将指导提高了 400%——你在关注吗？</li>
<li>投资高市盈率成长股</li>
<li>彼得·蒂尔抛售 NVIDIA 并削减特斯拉股份——人工智能泡沫即将破裂吗？</li>
<li>纽约证券交易所股票为投资者提供多种优质选择</li>
<li>为什么锂美洲可能是 2030 年的强劲投资——而不是 2025 年</li>
</ul>
<p><strong>想知道其他对 GILD 感兴趣的对冲基金持有哪些股票吗？</strong> 访问 HoldingsChannel.com 获取吉利德科学公司（NASDAQ:GILD - 免费报告）的最新 13F 文件和内部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0lMRA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0lMRA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在吉利德科学吗？</h2>
<p>在考虑吉利德科学之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而吉利德科学并不在名单上。</p>
<p>虽然吉利德科学目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

吉利德科学

<p>Handelsbanken Fonder AB 在第二季度增持了吉利德科学的股份，增幅为 6.3%，目前持有 1,164,320 股，价值为 129,088,000 美元。分析师们已提高了吉利德的目标价，普遍评级为 “适度买入”，目标价为 130.45 美元。吉利德第三季度的收益超出预期，报告每股收益为 2.47 美元，收入为 77.7 亿美元。该公司的市值为 1550.7 亿美元，并宣布 2025 财年的每股收益指导为 8.050-8.250 美元</p>

<p>Handelsbanken Fonder AB boosted its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 6.3% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,164,320 shares of the biopharmaceutical company's stock after purchasing an additional 69,440 shares during the quarter. Handelsbanken Fonder AB owned about 0.09% of Gilead Sciences worth $129,088,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>Handelsbanken Fonder AB 在第二季度增持了 Gilead Sciences, Inc.（NASDAQ:GILD - 免费报告）6.3% 的股份，根据其最近向证券交易委员会提交的 13F 表格。该公司在本季度购买了额外的 69,440 股后，持有生物制药公司 1,164,320 股股票。截至其最近的 SEC 文件，Handelsbanken Fonder AB 持有 Gilead Sciences 约 0.09% 的股份，价值 129,088,000 美元。</p>
</div><ul>
<li>3 Cash-Rich Stocks With High Growth Potential Right Now</li>
</ul>
<div class="lb-trans"><ul>
<li>目前具有高增长潜力的 3 只现金丰富股票</li>
</ul>
</div><p>Several other institutional investors have also recently made changes to their positions in GILD. One Wealth Advisors LLC increased its stake in Gilead Sciences by 34.8% during the 2nd quarter. One Wealth Advisors LLC now owns 9,163 shares of the biopharmaceutical company's stock valued at $1,016,000 after purchasing an additional 2,364 shares in the last quarter. Ariel Investments LLC increased its position in shares of Gilead Sciences by 7.7% during the first quarter. Ariel Investments LLC now owns 430,424 shares of the biopharmaceutical company's stock worth $48,229,000 after acquiring an additional 30,630 shares in the last quarter. Simplify Asset Management Inc. raised its holdings in shares of Gilead Sciences by 148.6% in the 2nd quarter. Simplify Asset Management Inc. now owns 52,890 shares of the biopharmaceutical company's stock worth $5,864,000 after acquiring an additional 31,618 shares during the last quarter. Sivik Global Healthcare LLC lifted its position in Gilead Sciences by 25.0% in the 2nd quarter. Sivik Global Healthcare LLC now owns 50,000 shares of the biopharmaceutical company's stock valued at $5,544,000 after acquiring an additional 10,000 shares in the last quarter. Finally, Wealth Management Associates Inc. acquired a new position in Gilead Sciences during the 2nd quarter valued at about $255,000. Institutional investors and hedge funds own 83.67% of the company's stock.</p>
<div class="lb-trans"><p>其他几家机构投资者最近也对 GILD 的持仓进行了调整。One Wealth Advisors LLC 在第二季度将其在 Gilead Sciences 的股份增加了 34.8%。One Wealth Advisors LLC 目前持有 9,163 股生物制药公司的股票，价值 1,016,000 美元，此前在上个季度购买了额外的 2,364 股。Ariel Investments LLC 在第一季度将其在 Gilead Sciences 的股份增加了 7.7%。Ariel Investments LLC 目前持有 430,424 股生物制药公司的股票，价值 48,229,000 美元，此前在上个季度收购了额外的 30,630 股。Simplify Asset Management Inc. 在第二季度将其在 Gilead Sciences 的股份增加了 148.6%。Simplify Asset Management Inc. 目前持有 52,890 股生物制药公司的股票，价值 5,864,000 美元，此前在上个季度收购了额外的 31,618 股。Sivik Global Healthcare LLC 在第二季度将其在 Gilead Sciences 的持仓增加了 25.0%。Sivik Global Healthcare LLC 目前持有 50,000 股生物制药公司的股票，价值 5,544,000 美元，此前在上个季度收购了额外的 10,000 股。最后，Wealth Management Associates Inc. 在第二季度获得了 Gilead Sciences 的新头寸，价值约 255,000 美元。机构投资者和对冲基金持有该公司 83.67% 的股份。</p>
</div><p>Get <strong>Gilead Sciences</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Gilead Sciences</strong> 警报：</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>GILD has been the topic of a number of recent research reports. Daiwa Capital Markets raised their target price on Gilead Sciences from $128.00 to $129.00 and gave the company an &#34;outperform&#34; rating in a report on Thursday, November 13th. Citigroup raised their price objective on Gilead Sciences from $125.00 to $135.00 and gave the company a &#34;buy&#34; rating in a research note on Wednesday, October 8th. Wells Fargo &amp; Company lifted their price objective on shares of Gilead Sciences from $140.00 to $145.00 and gave the stock an &#34;overweight&#34; rating in a report on Friday, October 31st. Scotiabank assumed coverage on shares of Gilead Sciences in a report on Thursday, November 13th. They issued a &#34;sector outperform&#34; rating and a $140.00 target price for the company. Finally, Royal Bank Of Canada raised their price target on shares of Gilead Sciences from $100.00 to $105.00 and gave the company a &#34;sector perform&#34; rating in a research report on Friday, October 31st. Two analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $130.45.</p>
<div class="lb-trans"><p>GILD 最近成为多份研究报告的主题。大和资本市场在 11 月 13 日的报告中将 Gilead Sciences 的目标价从 128.00 美元上调至 129.00 美元，并给予该公司 “跑赢大盘” 的评级。花旗集团在 10 月 8 日的研究报告中将 Gilead Sciences 的目标价从 125.00 美元上调至 135.00 美元，并给予该公司 “买入” 评级。富国银行在 10 月 31 日的报告中将 Gilead Sciences 的目标价从 140.00 美元上调至 145.00 美元，并给予该股票 “增持” 评级。加拿大丰业银行在 11 月 13 日的报告中开始覆盖 Gilead Sciences 的股票。他们给予该公司 “行业跑赢” 的评级和 140.00 美元的目标价。最后，加拿大皇家银行在 10 月 31 日的研究报告中将 Gilead Sciences 的目标价从 100.00 美元上调至 105.00 美元，并给予该公司 “行业表现” 的评级。两位分析师对该股票给予强烈买入评级，二十一位给予买入评级，三位给予持有评级。根据 MarketBeat.com 的数据，该公司目前的共识评级为 “适度买入”，共识目标价为 130.45 美元。</p>
</div><ul>
<li>Biotech Sector May Flip to Market Leader by Year-End</li>
</ul>
<div class="lb-trans"><ul>
<li>生物技术行业可能在年末转变为市场领头羊</li>
</ul>
</div><p><strong>Check Out Our Latest Research Report on GILD</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 GILD 的最新研究报告</strong></p>
</div><h2>Gilead Sciences Price Performance</h2>
<div class="lb-trans"><h2>Gilead Sciences 价格表现</h2>
</div><p>Shares of NASDAQ:GILD opened at $124.99 on Friday. The company has a market capitalization of $155.07 billion, a P/E ratio of 24.90, a price-to-earnings-growth ratio of 0.81 and a beta of 0.32. The company's 50-day moving average is $118.23 and its 200 day moving average is $113.37. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. Gilead Sciences, Inc. has a fifty-two week low of $88.07 and a fifty-two week high of $128.70.</p>
<div class="lb-trans"><p>NASDAQ:GILD 的股票在周五开盘价为 124.99 美元。该公司的市值为 1550.7 亿美元，市盈率为 24.90，市盈增长比率为 0.81，贝塔值为 0.32。该公司的 50 日移动平均线为 118.23 美元，200 日移动平均线为 113.37 美元。该公司的债务与股本比率为 1.13，速动比率为 1.15，流动比率为 1.32。Gilead Sciences, Inc. 的 52 周低点为 88.07 美元，52 周高点为 128.70 美元。</p>
</div><ul>
<li>3 Biotech Giants Gaining From U.S. Sales and Policy Shifts</li>
</ul>
<div class="lb-trans"><ul>
<li>3 家因美国销售和政策变化而受益的生物技术巨头</li>
</ul>
</div><p>Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.16 by $0.31. The business had revenue of $7.77 billion during the quarter, compared to the consensus estimate of $7.42 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The firm's quarterly revenue was up 3.0% compared to the same quarter last year. During the same quarter last year, the company posted $2.02 earnings per share. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, equities research analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.</p>
<div class="lb-trans"><p>Gilead Sciences（NASDAQ:GILD - 获取免费报告）最近在 10 月 30 日发布了季度财报。该生物制药公司报告本季度每股收益（EPS）为 2.47 美元，超出分析师共识预期的 2.16 美元，超出幅度为 0.31 美元。该公司本季度的收入为 77.7 亿美元，而共识预期为 74.2 亿美元。Gilead Sciences 的净利润率为 21.86%，股本回报率为 50.99%。该公司的季度收入较去年同期增长了 3.0%。去年同期，该公司每股收益为 2.02 美元。Gilead Sciences 已将其 2025 财年的指导目标设定为 8.050-8.250 每股收益。根据分析师的平均预测，Gilead Sciences, Inc. 预计本年度每股收益为 7.95 美元。</p>
</div><h2>Gilead Sciences Announces Dividend</h2>
<div class="lb-trans"><h2>Gilead Sciences 宣布分红</h2>
</div><p>The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 30th. Investors of record on Monday, December 15th will be paid a $0.79 dividend. The ex-dividend date is Monday, December 15th. This represents a $3.16 annualized dividend and a yield of 2.5%. Gilead Sciences's dividend payout ratio is presently 48.99%.</p>
<div class="lb-trans"><p>该公司最近还披露了季度分红，将于 12 月 30 日（星期二）支付。12 月 15 日（星期一）登记的投资者将获得 0.79 美元的分红。除息日为 12 月 15 日（星期一）。这代表着每年 3.16 美元的分红，收益率为 2.5%。Gilead Sciences 的分红支付比率目前为 48.99%。</p>
</div><h2>Insider Transactions at Gilead Sciences</h2>
<div class="lb-trans"><h2>Gilead Sciences 的内部交易</h2>
</div><p>In other news, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction on Monday, November 17th. The stock was sold at an average price of $125.23, for a total transaction of $313,075.00. Following the completion of the transaction, the chief financial officer owned 154,555 shares in the company, valued at approximately $19,354,922.65. This represents a 1.59% decrease in their position. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which can be accessed through this hyperlink. Also, CEO Daniel Patrick O'day sold 10,000 shares of Gilead Sciences stock in a transaction dated Tuesday, October 28th. The stock was sold at an average price of $119.39, for a total value of $1,193,900.00. Following the completion of the sale, the chief executive officer directly owned 581,203 shares of the company's stock, valued at approximately $69,389,826.17. This trade represents a 1.69% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 125,146 shares of company stock valued at $15,148,441 in the last three months. 0.27% of the stock is currently owned by company insiders.</p>
<div class="lb-trans"><p>在其他新闻中，首席财务官安德鲁·D·迪金森于 11 月 17 日星期一出售了 2,500 股该股票。股票的平均售价为 125.23 美元，总交易额为 313,075.00 美元。交易完成后，首席财务官在公司持有 154,555 股，价值约为 19,354,922.65 美元。这代表其持股减少了 1.59%。该交易已在与证券交易委员会的法律文件中披露，您可以通过此超链接访问。此外，首席执行官丹尼尔·帕特里克·奥戴于 10 月 28 日星期二出售了 10,000 股吉利德科学的股票。股票的平均售价为 119.39 美元，总价值为 1,193,900.00 美元。交易完成后，首席执行官直接持有 581,203 股公司股票，价值约为 69,389,826.17 美元。这笔交易代表其持股减少了 1.69%。有关此次出售的更多细节可在官方 SEC 披露中找到。在过去三个月中，内部人士共出售了 125,146 股公司股票，价值为 15,148,441 美元。目前，0.27% 的股票由公司内部人士持有。</p>
</div><h2>About Gilead Sciences</h2>
<div class="lb-trans"><h2>关于吉利德科学</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.</p>
<div class="lb-trans"><p>吉利德科学公司是一家生物制药公司，在美国、欧洲及国际上发现、开发和商业化满足医疗需求的药物。该公司提供 Biktarvy、Genvoya、Descovy、Odefsey、Truvada、Complera/Eviplera、Stribild、Sunlencs 和 Atripla 等产品用于治疗 HIV/AIDS；Veklury，一种用于静脉注射的药物，用于治疗 COVID-19；以及 Epclusa、Harvoni、Vemlidy 和 Viread 用于治疗病毒性肝炎。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Gilead Sciences</li>
<li>Retail Stocks Investing, Explained</li>
<li>Datavault AI Just Raised Guidance by 400%—Are You Paying Attention?</li>
<li>Investing in the High PE Growth Stocks</li>
<li>Peter Thiel Dumps NVIDIA and Slashes Tesla Stake—Is the AI Bubble About to Pop?</li>
<li>NYSE Stocks Give Investors a Variety of Quality Options</li>
<li>Why Lithium Americas Could Be a 2030 Power Play—Not a 2025 One</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过吉利德科学</li>
<li>零售股票投资解析</li>
<li>Datavault AI 刚刚将指导提高了 400%——你在关注吗？</li>
<li>投资高市盈率成长股</li>
<li>彼得·蒂尔抛售 NVIDIA 并削减特斯拉股份——人工智能泡沫即将破裂吗？</li>
<li>纽约证券交易所股票为投资者提供多种优质选择</li>
<li>为什么锂美洲可能是 2030 年的强劲投资——而不是 2025 年</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding GILD?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).</p>
<div class="lb-trans"><p><strong>想知道其他对 GILD 感兴趣的对冲基金持有哪些股票吗？</strong> 访问 HoldingsChannel.com 获取吉利德科学公司（NASDAQ:GILD - 免费报告）的最新 13F 文件和内部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0lMRA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=GILD"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Gilead Sciences Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在吉利德科学吗？</h2>
</div><p>Before you consider Gilead Sciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑吉利德科学之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而吉利德科学并不在名单上。</p>
</div><p>While Gilead Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然吉利德科学目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Handelsbanken Fonder AB 购买了 69,440 股吉利德科学公司（Gilead Sciences, Inc.）的股票 $GILD